22nd Century Group, Inc. (XXII) News
Filter XXII News Items
XXII News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XXII News Highlights
- 500 - Internal server error
- Over the past 9 days, the trend for XXII's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about XXII are IP and ACB.
Latest XXII News From Around the Web
Below are the latest news stories about 22nd Century Group Inc that investors may wish to consider to help them evaluate XXII as an investment opportunity.
7 A-Rated Biotech Stocks to Buy NowInvestors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. |
Four Cannabis Stocks for the Summer of 2021Cannabis stocks have resumed their upward trend. Here are four stocks to consider.ATLANTA, June 10, 2021 (GLOBE NEWSWIRE) -- Cannabis stocks have staged a rousing return in recent weeks after a quiet first half of 2021. Sales are on the rise this year as revenue and profits for many cannabis companies have increased significantly. During the global COVID-19 pandemic medical marijuana was deemed "essential,” which definitely had an impact on increased sales. U.S. legal cannabis sales grew 46% yea |
22nd Century Announces Closing of $40 Million Common Stock Registered Direct OfferingFinancing Provides Support to the Company’s Strategic Objectives Across All Its Plant Franchises.BUFFALO, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced that it closed the previously announced sale of 10 million shares of its common stock at a purchase price of $4.00 per share in a registered direct offering |
Reduced Nicotine Tobacco and Cannabinoid Innovator 22nd Century Group to Be Added to Russell 2000®, Russell 3000®, and Russell Global IndexesBUFFALO, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, is pleased to announce that it will be added to the Russell 2000®, Russell 3000®, and Russell Global Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021. “It is an honor to join |
Why 22nd Century Group, HEXO, and Canopy Growth Stocks All Popped TodayMarijuana stocks are growing again Monday -- with a little help from 22nd Century Group (NYSEMKT: XXII). In a pair of press releases, 22nd Century first announced that it is selling 10 million shares of stock to an institutional investor at $4 a share, in order to raise $40 million "to support the Company's strategic objectives across all of its plant franchises." Then 22nd Century announced that one of these "objectives" will be to partner with Aurora Cannabis (NASDAQ: ACB) to "actively explore commercial development opportunities" on tobacco and cannabis products. |
22nd Century Advances Initiatives to Strengthen and Maximize Revenue Opportunities in Hemp/Cannabis FranchiseClose Partnership With Aurora Cannabis Inc. to Enforce Shared Global Biosynthesis IP Rights Against Infringement and Actively Explore Commercial Development Opportunities; Monetization of Key Patented Technology Expected in Second Half of 2021Secures Strategic Partnerships With Two Leading Alkaloid Specialist Plant Breeders to Complete Full Scope of Upstream Capabilities Leads in Upstream Cannabinoid Value Chain to Accelerate the Development of New, Valuable Commercial Plant Lines in Two YearsCr |
22nd Century Announces $40 Million Common Stock Registered Direct OfferingFinancing Provides Support to the Company’s Strategic Objectives Across All Its Plant Franchises.BUFFALO, N.Y., June 07, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced that it has entered into a definitive agreement with one institutional investor for the sale of 10 million shares of its common stock at a purchase price of |
22nd Century Group: Disrupting The Plant-Based Markets With Improved Genetics22nd Century Group, Inc. (NYSE: XXII ) is a plant biotechnology company covering the tobacco, hemp and cannabis markets. “At our core, think of us as the Intel Inside of cannabis. We’re a disruptive plant-based biotechnology company,” said CEO Jim Mish, presenting at the virtual Benzinga Cannabis Capital Conference on Thursday. 22nd Century was founded on a mission to bring forward a product able to reduce the harm caused by nicotine-based cigarettes, and later expanded to other plant lines including marijuana, hemp, and a third –still undisclosed– alkaloid-based plant. The Tobacco Franchise: 22nd Century has developed a low nicotine strain of tobacco, which is aimed as a harm reduction alternative to the cigarette market. “We have a very deep moat around our IP, certainly within the to... |
Is 22nd Century Group a Buy Under $5?https://www.investing.com/news/stock-market-news/is-22nd-century-group-a-buy-under-5-2520252 |
8 Reddit Penny Stocks That May Withstand the Market MaelstromLooming uncertainty may be bad news for most Reddit penny stocks, but these eight may hold onto their gains, or head higher, from here. |